Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two-Year Ban On Device Tax Clinched In Tax-Extenders Bill, Passage Expected Soon

This article was originally published in Clinica

Executive Summary

House and Senate negotiators reached a compromise agreement early Dec. 16 to place a two-year delay on the medical device tax as part of a tax-extenders bill, a move hailed by the device and medical imaging industry. However, the House and Senate still have to vote on the bill, the Protecting Americans from Tax Hikes Act of 2015, which also includes a permanent extension of the research and development tax credit.

You may also be interested in...



Sen. Klobuchar Forming Coalition To Push For Both Device, Cadillac Tax Repeal

Sen. Amy Klobuchar, D-Minn., is putting together a coalition of lawmakers who favor repeal of both the medical device excise tax and the Affordable Care Act's so-called "Cadillac tax" on high-expense health-care plans.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel